FOLD - Amicus: One Down One To Go More In The Lab
Amicus Therapeutics (FOLD) received approval for Galafold (migalastat) for Fabry disease in August last year. On Jan. 7, it provided revenue data which showed that Galafold made $91M in those 6 months, beating guidance range of $80-$90M. The company has one other drug in late stage trials targeting Pompe disease. FOLD is cash rich, everything else looks good, and yet the stock has kept falling from the highs of July-August, at one point in early January almost reaching half its July figures. Since then, though, the company has gone up over 50%, so